Large placebo-controlled trials of SGLT2 inhibitors have assessed patients with type 2 diabetes, chronic kidney disease, and heart failure, but no previous trial has been specifically powered to assess kidney or cardiovascular effects in patients without diabetes. Here, SLC5A2 is linked to heart failure.